EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mayne Pharma Group's enterprise value is €170.4 Mil.
Mayne Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-51.3 Mil. Therefore, Mayne Pharma Group's EV-to-EBITDA for today is -3.32.
The historical rank and industry rank for Mayne Pharma Group's EV-to-EBITDA or its related term are showing as below:
HAM:HG6'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -52.92 Med: -1.36 Max: 48.82
Current: -3.3
During the past 13 years, the highest EV-to-EBITDA of Mayne Pharma Group was 48.82. The lowest was -52.92. And the median was -1.36.
HAM:HG6's EV-to-EBITDA is ranked worse than 100% of 710
companies
in the Drug Manufacturers industry
Industry Median: 14.09
vs HAM:HG6: -3.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Mayne Pharma Group EV-to-EBITDA Historical Data
The historical data trend for Mayne Pharma Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mayne Pharma Group's EV-to-EBITDA
For the Drug Manufacturers - General subindustry, Mayne Pharma Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's EV-to-EBITDA falls into.
Mayne Pharma Group's current Enterprise Value is €170.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mayne Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-51.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (HAM:HG6) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mayne Pharma Group's PE Ratio for today is calculated as:
Mayne Pharma Group's share price for today is €2.82.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mayne Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.846.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Mayne Pharma Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HAM:HG6 has been successfully added to your 